Venture Visionary Partners LLC Sells 6,100 Shares of Perrigo Company plc (NYSE:PRGO)

Venture Visionary Partners LLC lessened its stake in Perrigo Company plc (NYSE:PRGO) by 28.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 15,296 shares of the company’s stock after selling 6,100 shares during the quarter. Venture Visionary Partners LLC’s holdings in Perrigo were worth $401,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of PRGO. Vanguard Group Inc. raised its stake in shares of Perrigo by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 14,994,309 shares of the company’s stock valued at $482,517,000 after buying an additional 91,322 shares during the period. Quadrature Capital Ltd purchased a new stake in Perrigo during the fourth quarter valued at about $313,000. Park Avenue Securities LLC boosted its position in Perrigo by 4.3% during the first quarter. Park Avenue Securities LLC now owns 11,330 shares of the company’s stock worth $365,000 after purchasing an additional 465 shares during the period. State of Michigan Retirement System increased its stake in shares of Perrigo by 2.2% in the first quarter. State of Michigan Retirement System now owns 33,258 shares of the company’s stock worth $1,071,000 after purchasing an additional 700 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in shares of Perrigo by 2.2% in the first quarter. Principal Financial Group Inc. now owns 525,236 shares of the company’s stock valued at $16,907,000 after purchasing an additional 11,474 shares during the period. Hedge funds and other institutional investors own 95.91% of the company’s stock.

Perrigo Stock Down 0.1 %

PRGO opened at $25.83 on Wednesday. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.99 and a quick ratio of 1.24. Perrigo Company plc has a one year low of $23.89 and a one year high of $34.60. The firm has a market capitalization of $3.52 billion, a P/E ratio of -28.08 and a beta of 0.48. The company has a fifty day moving average price of $26.81 and a 200-day moving average price of $27.94.

Perrigo (NYSE:PRGO) last announced its earnings results on Friday, August 2nd. The company reported $0.53 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.07. Perrigo had a positive return on equity of 6.79% and a negative net margin of 2.81%. The business had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same period in the prior year, the company earned $0.63 EPS. The company’s quarterly revenue was down 10.7% compared to the same quarter last year. Equities research analysts expect that Perrigo Company plc will post 2.56 earnings per share for the current fiscal year.

Perrigo Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 17th. Shareholders of record on Friday, August 30th were paid a $0.276 dividend. The ex-dividend date of this dividend was Friday, August 30th. This represents a $1.10 dividend on an annualized basis and a yield of 4.27%. Perrigo’s dividend payout ratio (DPR) is currently -119.57%.

Analyst Ratings Changes

A number of research firms recently weighed in on PRGO. Jefferies Financial Group reiterated a “hold” rating and issued a $30.00 price objective (down from $50.00) on shares of Perrigo in a research note on Monday, September 23rd. Canaccord Genuity Group reiterated a “buy” rating and issued a $42.00 price target on shares of Perrigo in a research report on Monday, September 30th. StockNews.com raised Perrigo from a “hold” rating to a “buy” rating in a report on Thursday, October 17th. Finally, Piper Sandler reduced their target price on Perrigo from $36.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.00.

Insider Buying and Selling

In other Perrigo news, Director Katherine C. Doyle sold 8,954 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $27.30, for a total value of $244,444.20. Following the transaction, the director now owns 6,009 shares in the company, valued at approximately $164,045.70. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Perrigo news, EVP Svend Andersen sold 28,300 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $27.75, for a total value of $785,325.00. Following the sale, the executive vice president now owns 73,553 shares in the company, valued at approximately $2,041,095.75. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Katherine C. Doyle sold 8,954 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $27.30, for a total value of $244,444.20. Following the transaction, the director now directly owns 6,009 shares of the company’s stock, valued at approximately $164,045.70. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,254 shares of company stock valued at $1,411,969 over the last three months. 0.70% of the stock is owned by company insiders.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.